MedTrace Logo

Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)

NCT01270672 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-12-11

No results posted yet for this study

Summary

The purpose of this study is to determinate the effect of a pre-treatment with carvedilol, a alpha- and beta-adrenergic receptor blocker, on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The investigators hypothesize that carvedilol will attenuate the cardiovascular and subjective response to MDMA.

Conditions

  • Mood Disorder
  • Substance-Related Disorders
  • Amphetamine-Related Disorders

Interventions

DRUG

3,4-Methylenedioxymethamphetamine

125 mg per os, single dose

DRUG

carvedilol

50 mg per os, single dose

DRUG

placebo

capsules identical to MDMA or carvedilol

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270672 on ClinicalTrials.gov